Boston Scientific (BSX) Liabilities and Shareholders Equity (2009 - 2026)

Boston Scientific has disclosed Liabilities and Shareholders Equity across 18 years of filings, most recently posting $44.4 billion for Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $44.4 billion, up 10.49% year-over-year; the trailing twelve-month figure through Mar 2026 was $172.3 billion (up 11.36% YoY), and the FY2025 annual result was $43.7 billion, up 10.86% from the prior year.
• Liabilities and Shareholders Equity came in at $44.4 billion for Q1 2026 at Boston Scientific, up from $43.7 billion in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $44.4 billion in Q1 2026 to a low of $31.9 billion in Q3 2022.
• The 5-year median for Liabilities and Shareholders Equity is $36.7 billion (2024), against an average of $37.0 billion.
• Across the five-year window, Liabilities and Shareholders Equity advanced 0.22% in 2022 and grew 12.16% in 2025, its largest moves.
• Boston Scientific's Liabilities and Shareholders Equity stood at $32.5 billion in 2022, then rose by 8.21% to $35.1 billion in 2023, then climbed by 12.12% to $39.4 billion in 2024, then climbed by 10.86% to $43.7 billion in 2025, then rose by 1.55% to $44.4 billion in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $44.4 billion (Q1 2026), $43.7 billion (Q4 2025), and $42.7 billion (Q3 2025), per Business Quant data.